# 6334
Yesterday in NEJM: Cardiovascular Risks Of Taking Azithromycin I wrote about a study that found a `small absolute increase in cardiovascular deaths’ among patients taking the macrolide antibiotic Azithromycin when compared to a control group taking no antibiotics or with taking amoxicillin.
In response to that study, the FDA has released the following statement:
FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death
[05-17-2012] The U.S. Food and Drug Administration (FDA) is aware of the study published in the New England Journal of Medicine, on May 17, 2012, that compared the risks of cardiovascular death in patients treated with azithromycin (Zithromax), amoxicillin, ciprofloxacin (Cipro), levofloxacin (Levaquin), and no antibacterial drug. The study reported a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment. FDA is reviewing the results from this study and will communicate any new information that results from the FDA review.
Patients taking azithromycin should not stop taking their medicine without talking to their healthcare professional.
Healthcare professionals should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering antibacterial drugs. (See additional information below.)
Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. Prolongation of the QT interval can lead to torsades de pointes (TdP), an abnormal heart rhythm, which can be fatal. Azithromycin was the only macrolide examined in the published study; the study did not address other macrolide antibacterial drugs, such as clarithromycin (Biaxin) and erythromycin, regarding the potential for cardiovascular death.
In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP. The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low. The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.
FDA-approved indications for azithromycin include:
- Acute bacterial exacerbations of chronic pulmonary disease
- Acute bacterial sinusitis
- Community-acquired pneumonia
- Pharyngitis/tonsillitis
- Uncomplicated skin and skin structure infections
- Urethritis and cervicitis
- Genital ulcer disease
FDA will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review.
Related Post:
- CDC HAN Update On Fungal Meningitis Outbreak
- FDA: Ameridose Announces Voluntary Recall Of All Products
- FDA Statement On Conditions Reported At NECC Facility
- The Narrow Margin
- FDA: Exserohilum Found In Unopened Vials Of NECC Methylprednisolone
- CDC/FDA: Multistate Fungal Meningitis Outbreak – Oct 15th
- CDC Update: Multi State Meningitis Outbreak – Oct 11th
- FDA Advice On Safe Use Of Neti Pots
- FDA Warning On Fake Adderall
- FDA Releases 2nd Edition Of the `Bad Bug Book’
- Kids, Colds, And OTC Meds
- FDA Approves 2011-2012 Seasonal Influenza Vaccines
- Because Everyday Is Fry Day
- Poll: Despite FDA Warning Parents Use OTC Cold Remedies For Kids Under 2
- FDA: Fluzone Vaccine Safety
- Salmonella-Related Egg Recall Expands
- Study: MLV Found In CFS Patients
- CDC Investigating Food-Related Typhoid Outbreak
- FDA Approves 2010-2011 Flu Vaccines
- FDA Farm Antibiotic Guidance Meets Resistance
- FDA Warns On Fake Tamiflu
- FDA Calls For Temporary Halt To Using Rotarix Vaccine
- FDA Warning On Extortion Scam
- Flu Email Scams
- ECDC: Multidrug Resistant Infections Increasing In Europe
- CHP: Review Of NDM-1 In Hong Kong
- Referral: McKenna On Resistant Gonorrhea
- Study: Antimicrobial Prescribing Practices During The 2009 Pandemic
- ECDC Response Plan To Multi-Drug Resistant Gonorrhea
- WHO: Urgent Action Needed On Resistant Gonorrhea
- Referral: McKenna Times Four
- HPA: Healthcare-Associated Infection (HCAI) Survey
- NEJM: Cardiovascular Risks Of Taking Azithromycin
- Video: Maryn McKenna On Antibiotic Resistance
- ECDC Comment On Drug Resistant TB In India
- Get Smart About Antibiotics Week
- CDDEP: Mapping Resistance
- NDM-1: One Year Later
- The Global Spread Of Drug Resistant Salmonella
- Study: Prior Antibiotic Use & MRSA In Children
- ECDC: Defining Bacterial Drug Resistance
- IDSA: Educational Guidelines Lower Antibiotic Use
- Going, Going, Gonorrhea
- The Path Of Increased Resistance
- Updating Hong Kong’s Scarlet Fever Outbreak
- When Old Bacteria Learns New Tricks
- Study: Sub-Therapeutic Antibiotic Exposure Drives Resistance
- UK: `New MRSA’ Strain Spreading
Widget by [ Iptek-4u ]